Business Context and Reporting Period
This Form 8-K was filed by Ikena Oncology, Inc. on April 15, 2021, under Item 5.02 and Item 9.01. The provided request metadata identifies Imagenebio, Inc., but the filing identifies the registrant as Ikena Oncology, Inc. The company is a biopharmaceutical company focused on oncology drug development.
Key Financial Metrics
The filing does not provide revenue, net income, cash flow, margins, debt, liquidity, or other financial metrics. It is an event-based filing concerning a board appointment.
Material Changes
- The board unanimously appointed Dr. Maria Koehler as an independent director on April 15, 2021.
- The appointment filled a newly created vacancy resulting from an increase in board size from six to seven directors.
- Dr. Koehler joined the Class I director slate, with a term expiring at the 2022 Annual Meeting of Stockholders.
- She will receive compensation consistent with other non-employee directors under the company’s initial public offering compensation arrangements.
- Dr. Koehler entered into the company’s standard form of indemnification agreement.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The board determined that Dr. Koehler is independent and qualified under applicable SEC and Nasdaq requirements. The filing states that there are no arrangements or understandings related to her election, no family relationships with directors or executive officers, and no reportable material interests under Item 404(a) of Regulation S-K.
Dr. Koehler’s qualifications are described as including leadership experience in oncology drug development at various biopharmaceutical companies. A related press release was filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the registrant identity, because the request metadata names Imagenebio, Inc., while the filing names Ikena Oncology, Inc.
- Review Exhibit 99.1 for additional details about Dr. Koehler’s appointment and qualifications.
- Confirm the board’s updated composition, Class I term expiration, and director compensation arrangements in subsequent filings.
- Consult the company’s periodic reports for financial condition, liquidity, operating results, and development-program updates, none of which are provided in this Form 8-K.